Novavax Inc (NVAX) is a publicly traded Healthcare sector company. As of May 20, 2026, NVAX trades at $9.33 with a market cap of $1.47B and a P/E ratio of -17.12. NVAX moved +4.33% today. Year to date, NVAX is +24.82%; over the trailing twelve months it is +14.99%. Its 52-week range spans $5.01 to $15.22. Analyst consensus is neutral with an average price target of $11.60. Rallies surfaces NVAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NVAX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NVAX recently traded at $9.33. Market cap is $1.47B. P/E ratio is -17.12. Revenue is $596.34M.
| Metric | Value |
|---|---|
| Price | $9.33 |
| Market Cap | $1.47B |
| P/E Ratio | -17.12 |
| EPS | $-0.54 |
| Dividend Yield | 0.11% |
| 52-Week High | $15.22 |
| 52-Week Low | $5.01 |
| Volume | 4.37M |
| Avg Volume | 0 |
| Revenue (TTM) | $596.34M |
| Net Income | $-87.83M |
| Gross Margin | 84.97% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.12B | $440.30M | $2.72 |
| 2024 | $682.16M | $-187.50M | $-1.23 |
| 2023 | $983.71M | $-545.06M | $-5.41 |
| 2022 | $1.98B | $-657.94M | $-8.42 |
5 analysts cover NVAX: 0 strong buy, 2 buy, 1 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $11.60.